Management of chronic hepatitis B: An update

Swiss Medical Weekly

Volumn 141, Issue SEPTEMBER, 2011, Pages

  Negro, Francesco ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Chronic hepatitis B; Cirrhosis; Entecavir; Hepatitis B virus; Tenofovir

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2A INTERFERON; CREATININE; EFAVIRENZ; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HESPERADIN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; PHOSPHATE; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; CREATININE BLOOD LEVEL; DISEASE CARRIER; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOLOGICAL TOLERANCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; NEPHROTOXICITY; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS PARTICLE; VIRUS STRAIN; BLOOD; DRUG EFFECT; VIRUS LOAD;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; PRACTICE GUIDELINES AS TOPIC; VIRAL LOAD;

EID: 80053902198     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2011.13264     Document Type: Review

References (58)

1. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol. 2005;34(Suppl 1):S1-3. (Pubitemid 43197742)
2. Weber A, Boege Y, Reisinger F, Heikenwälder M. Chronic liver inflammation and hepatocellular carcinoma: persistence matters. Swiss Med Wkly. 2011;141:w13197.
3. http://www.ecdc.europa.eu/en/publications/Publications/ TER-100914-Hep-B-C%20-EU-neighbourhood.pdf (accessed July 31, 2010)
4. Nardone A, Anastassopoulou CG, Theeten H, Kriz B, Davidkin I, Thierfelder W, O'Flanagan D, et al. A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiol Infect. 2009;137:961-9.
5. Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill. 2008;13.
6. Kammerlander R, Zimmermann H. Epidemiology of hepatitis B in Switzerland. Soz Praventivmed. 1998;43(Suppl 1):S27-30, S101-4.
7. Bart PA, Jacquier P, Zuber PL, Lavanchy D, Frei PC. Seroprevalence of HBV (anti-HBc, HBsAg and anti-HBs) and HDV infections among 9006 women at delivery. Liver. 1996;16:110-6. (Pubitemid 26128713)
8. Russmann S, Dowlatshahi EA, Printzen G, Habicht S, Reichen J, Zimmermann H. Prevalence and associated factors of viral hepatitis and transferrin elevations in 5036 patients admitted to the emergency room of a Swiss university hospital: cross-sectional study. BMC Gastroenterol. 2007;7:5.
9. Frischknecht F, Sell W, Trummer I, Brühwiler H. Serological testing for infectious diseases in pregnant women: are the guidelines followed? Swiss Med Wkly. 2011;140:w13138.
10. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139:483-90.
11. Liaw YF, Brunetto MR, Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antivir Ther. 2010;15(Suppl 3):25-33.
12. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-42.
13. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-2.
14. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335-52.
15. Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int. 2009;3:425-33.
16. van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology. 2004;39:804-10. (Pubitemid 38337661)
17. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TMK, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135:459-67.
18. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137:2002-9.
19. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeA-gpositive chronic hepatitis B. Hepatology. 2008;47:428-34. (Pubitemid 351280710)
20. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44:675-84. (Pubitemid 44433724)
21. Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, Leung NW, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005;128:1890-7. (Pubitemid 40824700)
22. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol. 2009;51:581-92.
23. Volz T, Lutgehetmann M, Wachtler P, Jacob A, Quaas A, Murray JM, Dandri M, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology. 2007;133:843-52. (Pubitemid 47374140)
24. Sonneveld MJ, Rijckborst V, Boucher CA, Zwang L, Beersma MF, Hansen BE, Janssen HL. A comparison of two assays for quantification of hepatitis B surface antigen in patients with chronic hepatitis B. J Clin Virol. 2011 May 16.
25. Lau GK, Marcellin P, Brunetto MR, Piratvisuth T, Kapprell HP, Button P, Batrla R, et al. On-treatment HBsAg decline during peginterferon alfa-2a (40kD) + lamivudine in patients with HBeAg-positive CHB as a potential predictor of durable off-treatment response. Hepatology. 2008;48(Suppl):714A.
26. Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol. 2009;50:1084-92.
27. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009;49:1141-50.
28. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology. 2010;52:454-61.
29. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52:1251-7.
30. Moucari R, Marcellin P. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. Liver Int. 2011;31(Suppl 1):122-8.
31. Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients. Hepatology. 2011;53:1054-5.
32. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, et al. IFN-α inhibits HBV transcription and replication by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. (in press).
33. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology. 2010;139:491-8.
34. Lee CM, Ong GY, Lu SN, Wang JH, Liao CA, Tung HD, Chen TM, et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol. 2002;37:669-74.
35. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003;37:748-55. (Pubitemid 36397384)
36. Lim S, Aung M, Sutedja D, Lee Y, Lee G, Fernandes ML, Lai V, Dan Y. Treatment induced HBeAg seroconversion is less durable than spontaneous seroconversion. Hepatology. 2010;52(Suppl):442A.
37. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132-43.
38. Heathcote JE, Gane EJ, deMan RA, Chan S, George J, Tsai NC, et al. Long-term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103): preliminary analysis. Hepatology. 2010;52(Suppl):556A.
39. Marcellin P, Heathcote EJ, Buti M, Krastev Z, Jacobson I, de Man RA, et al. HBsAg kinetics in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumarate (TDF) for up to 4 years. J Hepatol. 2011;54(Suppl 1):S297.
40. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133:1437-44. (Pubitemid 350029745)
41. Chevaliez S, Hezode C, Grare M, Pawlotsky JM. Long-term monitoring of HBsAg kinetics and prediction of HBsAg clearance in patients with chronic hepatitis B treated with nucleoside/nucleotide analogues. Hepatology. 2010;52(Suppl):506A.
42. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL. Prediction of HBsAg loss using HBsAg decline after long-term virological response to nucleos(t)ide analogue therapy for chronic hepatitis B. Hepatology. 2010;52(Suppl):509A.
43. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486-95.
44. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422-30.
45. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology. 2011;53:763-73.
46. Lampertico P, Viganò M, Soffredini R, Facchetti F, Minola E, Suter F, et al. Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice: the Italian multicenter experience. Hepatology. 2010;52(Suppl):514A.
47. Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol. 2010;52:791-9.
48. Fung J, Lai CL, Yuen J, Cheng C, Wu R, Wong DK, Seto WK, et al. Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 Years. Hepatology. 2011;53:1148-53.
49. Bihl F, Alaei M, Negro F. The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians. Swiss Med Wkly. 2010;140:154-9.
50. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol. 2010;52:493-500.
51. Ha NB, Trinh HN, Ha NB, Nguyen HA, Nguyen K, Nguyen MH. Response to higher dose of entecavir (ETV) 1.0 mg daily in patients with chronic hepatitis B (CHB) and partial response to ETV 0.5 mg daily. Hepatology. 2010;52(Suppl):535A.
52. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010;51:73-80.
53. Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S, Suarez E,et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology. 2010;139:1207-17.
54. Curtis M, Hinkle J, Harris J, Borroto-Esoda K, Zhu Y. Tenofovir is equally active in vitro against wild-type HBV clinical isolates of genotypes A-H. Hepatology. 2008;48(Suppl):735A.
55. Marcellin P, Buti M, Krastev Z, Gurel S, Di Bisceglie AM, Odin JA, et al. Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (study 102): preliminary analysis. Hepatology. 2010;52(Suppl):555A.
56. th International Congress on Drug Therapy in HIV Infection, November 7-11, 2010, Glasgow, UK, abstract P6 .
57. thInternational Congress on Drug Therapy in HIV Infection, November 7-11, 2010, Glasgow, UK, abstract P86.
58. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62-72.